Advertisement
Advertisement
U.S. markets close in 5 hours 1 minute
Advertisement
Advertisement
Advertisement
Advertisement

CARsgen Therapeutics Holdings Limited (2171.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
10.700-0.420 (-3.78%)
At close: 04:08PM HKT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.120
Open11.240
Bid10.580 x N/A
Ask10.700 x N/A
Day's Range10.480 - 11.240
52 Week Range9.680 - 57.250
Volume1,180,500
Avg. Volume1,732,856
Market Cap6.102B
Beta (5Y Monthly)N/A
PE Ratio (TTM)1.60
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 2171.HK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit

      SHANGHAI, September 21, 2022--CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 7th Annual CAR-TCR Summit, in Boston, Massachusetts, the Company gave an oral presentation on the North America Phase 2 clinical trial of zevorcabtagene autoleucel ("zevor-cel", R&D code: CT053), an autologous CAR T-cell product candidate against BCMA. This multi-center

    • Business Wire

      CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina

      SHANGHAI, September 02, 2022--CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the company’s Current Good Manufacturing Practice (CGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America ("The RTP GMP Manufacturing Facility") has started GMP production of autologous CAR T-cell products and s

    • PR Newswire

      CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

      CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results.

    Advertisement
    Advertisement